Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05174650 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Apr 30, 2025, no change to tracked fieldsv8-v9
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: 37 to 27
    • Study sites: 19 to 17
    v7
  3. Study sites: 11 to 19
    • Eligibility criteria expanded, about 10 words
    v6
  4. Study sites: 1 to 11v5
  5. Start date changed from estimate of Apr 2022 to Apr 20, 2022v4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jan 2022 to Apr 2022
    • Study sites: 0 to 1
    v3
  2. Start date: Dec 2021 to Jan 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study trial is a open-label, single-arm, multicenter phase II trial investigating the combined treatment of atezolizumab and derazantinib in patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements
Trial Details
NCT Number NCT05174650
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Conditions
(from sponsor)		 Intrahepatic Cholangiocarcinoma
Related terms Cholangiocarcinoma
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov